Skip to Content
Merck
All Photos(1)

Documents

Safety Information

SBR00044

Sigma-Aldrich

Pristinamycin

≥98% (Assay)

Synonym(s):

Pristinamycine

Sign Into View Organizational & Contract Pricing


About This Item

UNSPSC Code:
51283802
NACRES:
NA.76

Quality Level

Assay

≥98% (Assay)

form

powder

color

white to faint yellow

antibiotic activity spectrum

Gram-positive bacteria

Mode of action

protein synthesis | inhibits

storage temp.

2-8°C

SMILES string

CN(C)C1=CC=C(C[C@@H](C(N2CCC(C[C@H]2C(N[C@@H](C3=CC=CC=C3)C(O[C@H](C)[C@H](NC(C4=NC=CC=C4O)=O)C5=O)=O)=O)=O)=O)N(C)C([C@H]6N(C([C@@H](N5)CC)=O)CCC6)=O)C=C1.O=C(N7C(C(O[C@H](C(C)C)[C@H](C)/C=C/C(NC/C=C/C(C)=C/[C@@H](O)CC(C8)=O)=O)=O)=CCC7)C9=COC8=N9

General description

Pristinamycin is a broad-spectrum streptogramin antibiotic composed of two components, pristinamycin IA (a macrolide) and pristinamycin IIA (a streptogramin A-type antibiotic). These components exhibit strong synergistic antibacterial activity against a wide range of Gram-positive and some Gram-negative bacteria, including resistant strains. Pristinamycin is derived from Streptomyces species and can also be produced by the genus Xenorhabdus. It is commonly used in cell biology applications to prevent the growth of bacterial contaminants and ensure the purity of cell lines. Each component of pristinamycin inhibits protein elongation by binding to the 50S ribosomal subunit, making pristinamycin a bacteriostatic antibiotic.

Application

Pristinamycin has been used:

  • in cloning and sequencing of genes involved in the biosynthesis of the depsipeptide antibiotics pristinamycins I (PI) produced by Streptomyces pristinaespiralis
  • in a study on inducible gene expression system in mycobacteria

Biochem/physiol Actions

Mode of Action: Involves two mechanisms: protein synthesis and cell wall synthesis. Pristinamycin effectively inhibits bacterial growth and exhibits bacteriostatic or bactericidal effects against susceptible bacteria.
  1. Inhibition of protein synthesis: Pristinamycin binds to the 50S ribosomal subunit in bacterial cells, thereby inhibiting the formation of peptide bonds during protein synthesis. This disrupts the translation process and prevents the production of essential proteins necessary for bacterial growth and survival.
  2. Interference with cell wall synthesis: Pristinamycin also interferes with the synthesis of bacterial cell walls. It inhibits the transpeptidation step of peptidoglycan biosynthesis, which is essential for the cross-linking of cell wall components. This leads to the weakening of the bacterial cell wall and eventual cell lysis


Activity spectrum: Pristinamycin shows anti-bacterial activity against Gram-positive bacteria like Staphylococcus spp. and Streptococcus spp. Pristinamycin displays antimicrobial activity against macrolide-resistant Mycoplasma genitalium infection.

Features and Benefits

  • Broad-spectrum activity: Pristinamycin is effective against a wide range of bacteria, including both Gram-positive and Gram-negative bacteria, as well as resistant strains.
  • Synergistic effect: The two components of pristinamycin work together to produce a synergistic effect, meaning that they are more effective together than they are individually.
  • Versatility: Pristinamycin can be used in Cell Biology and Biochemical applications

Other Notes

For additional information on our range of Biochemicals, please complete this form.

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Regulatory Listings

Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.

JAN Code

SBR00044-VAR:
SBR00044-5MG:


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Pristinamycin I biosynthesis in Streptomyces pristinaespiralis: molecular characterization of the first two structural peptide synthetase genes
Lagard VC et al.
Journal of Bacteriology, 179, 05-13 (1997)
Jönike Dreyer et al.
Frontiers in microbiology, 9, 3177-3177 (2019-01-09)
The genus Xenorhabdus of the family Enterobacteriaceae, are mutualistically associated with entomopathogenic nematodes of the genus Steinernema. Although most of the associations are species-specific, a specific Xenorhabdus sp. may infect more than one Steinernema sp. During the Xenorhabdus-Steinernema life cycle
Eden C Cooper et al.
The Journal of antimicrobial chemotherapy, 69(9), 2319-2325 (2014-06-04)
Osteoarticular infections with Gram positive bacteria present an increasing challenge in an era of multidrug-resistant organisms. Prolonged intravenous antibiotic treatment is often required, with associated risks, costs and difficulties with administration; a safe, effective oral option would be ideal for
Tim R H Read et al.
Emerging infectious diseases, 24(2), 328-335 (2018-01-20)
High levels of macrolide resistance and increasing fluoroquinolone resistance are found in Mycoplasma genitalium in many countries. We evaluated pristinamycin for macrolide-resistant M. genitalium in a sexual health center in Australia. Microbiologic cure was determined by M. genitalium-specific 16S PCR
Pristinamycin-inducible gene regulation in mycobacteria
Forti F et al.
Journal of Biotechnology, 140, 270-277 (2009)

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service